United States · FDA National Drug Code directory

Exjade

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
0078-0468_17c39217-5502-420d-8d2e-799626756189
Product NDC
0078-0468
Form
TABLET, FOR SUSPENSION
Composition / generic term
deferasirox
Labeler
Novartis Pharmaceuticals Corporation
Marketing category
NDA
Marketing start / end (source format)
20051130
Source listing expiry
20271231

Source-listed ingredients

  • DEFERASIROX — 125 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0468-15) · 0078-0468-15

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →